Medivir and Tango Therapeutics sign license agreement for preclinical asset
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that it has entered into a license agreement with US biotech company Tango Therapeutics for one of Medivir’s preclinical research programs. Under the terms of the agreement, Medivir will receive an undisclosed upfront payment and is eligible to receive multiple undisclosed development and commercial milestones as well as low single-digit royalties on future products. “We are pleased to see one of our promising preclinical assets finding a new home for further exploration by a very exciting company” said Dr Christina